Insider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 2,423 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 2,423 shares of Evolus stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $12.72, for a total transaction of $30,820.56. Following the sale, the chief financial officer now directly owns 151,778 shares in the company, valued at approximately $1,930,616.16. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Sandra Beaver also recently made the following trade(s):

• On Tuesday, March 19th, Sandra Beaver sold 5,672 shares of Evolus stock. The shares were sold at an average price of $13.92, for a total value of $78,954.24.
• On Thursday, February 22nd, Sandra Beaver sold 1,821 shares of Evolus stock. The shares were sold at an average price of $13.08, for a total value of $23,818.68.

Evolus Price Performance

Evolus stock traded up $0.16 during mid-day trading on Tuesday, hitting $12.77. The stock had a trading volume of 440,091 shares, compared to its average volume of 645,698. The firm has a market capitalization of $799.53 million, a P/E ratio of -12.16 and a beta of 1.47. The company has a current ratio of 3.21, a quick ratio of 2.96 and a debt-to-equity ratio of 6.54. The firm's 50 day moving average is $13.09 and its 200 day moving average is $11.70. Evolus, Inc. has a one year low of $7.07 and a one year high of $15.43.

Evolus (NASDAQ:EOLS - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The company had revenue of $61.00 million for the quarter, compared to analysts' expectations of $61.14 million. On average, sell-side analysts forecast that Evolus, Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on EOLS shares. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, May 8th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday, May 8th. Finally, Barclays raised shares of Evolus from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $10.00 to $16.00 in a report on Monday, January 29th.

Institutional Trading of Evolus

Hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC grew its holdings in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company's stock valued at $41,735,000 after purchasing an additional 2,477,623 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Evolus in the 1st quarter worth about $11,628,000. Vanguard Group Inc. increased its stake in Evolus by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company's stock worth $24,666,000 after buying an additional 741,451 shares during the period. Stonepine Capital Management LLC increased its stake in Evolus by 14.9% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,179,004 shares of the company's stock worth $47,336,000 after buying an additional 672,807 shares during the period. Finally, Rice Hall James & Associates LLC increased its stake in Evolus by 61.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,105,159 shares of the company's stock worth $10,101,000 after buying an additional 421,890 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.